Cancer Treatment Reviews
Volume 36, Issue 6 , Pages 501-506 , October 2010

Patient-reported outcomes after cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: A systematic review

  • Giuseppe Colloca

      Affiliations

    • Division of Medical Oncology, ASL-1 Imperiese, Ospedale Giovanni Borea, Via Giovanni Borea, 56 I-18038 Sanremo, Imperia, Italy
    • Corresponding Author InformationCorresponding author. Address: Division of Medical Oncology, Ospedale Giovanni Borea, Via G. Borea, 56, I-18038, Sanremo (Imperia), Italy. Tel.: +39 0183 960352; fax: +39 0183 961283.
    • ,
  • Antonella Venturino

      Affiliations

    • Division of Medical Oncology, ASL-1 Imperiese, Ospedale Giovanni Borea, Via Giovanni Borea, 56 I-18038 Sanremo, Imperia, Italy
    • ,
  • Franco Checcaglini

      Affiliations

    • Division of Radiotherapy, ASL-1 Umbria, Ospedale Civile Città di Castello, Via Engels I-06012, Città di Castello Perugia, Italy

Received 13 December 2009 ,Revised 27 January 2010 ,Accepted 1 February 2010.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249
  2. Newschaffer CJ, Otani K, McDonald MK, et al. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst. 2000;92:613–621
  3. Scher HI, Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology. 2000;55:323–327
  4. van Kleffens T, Van Baarsen B, Hoekman K, et al. Clarifying the term ‘palliative’ in clinical oncology. Eur J Cancer Care. 2004;13:263–271
  5. Petrylak DP, Tangen CM, Maha PH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–1520
  6. Tannock IF, De Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512
  7. Hamberg P, Verhagen PC, de Wit R. When to start cytotoxic therapy in asymptomatic patient with hormone refractory prostate cancer?. Eur J Cancer. 2008;44:1193–1197
  8. Schnadig ID, Beer TM. Optimal timing of chemotherapy in androgen independent prostate cancer. Urol Oncol. 2009;27:97–100
  9. Lipscomb J, Gotay CC, Snyder CE. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer J Clin. 2007;57:278–300
  10. Acquadro C, Berzon R, Dubois D, et al. Incorporating the patient’s perspective into drug development and communication: an ad hoc task force report of the patient-reported outcomes (PRO) harmonization group meeting at the food and drug administration. February 16, 2001. Value Health. 2003;6:522–531
  11. Arpinelli F, Bamfi F. The FDA guidance for industry on PROs: the point of view of a pharmaceutical company. Health Qual Life Outcomes. 2006;4:85
  12. Yancik R. Cancer burden in the aged. An epidemiologic and demographic overview. Cancer. 1997;80:1273–1283
  13. Stephens RJ, Hopwood P, Girling DJ. Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer. 1999;79:538–544
  14. Bottomley A, Vanvoorden V, Flechtner H, et al. The challenges and achievements involved in implementing quality of life research in cancer clinical trials. Eur J Cancer. 2003;39:275–285
  15. Joly F, Vardy J, Pintilie M, et al. Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol. 2007;18:1935–1942
  16. Berthold DR, Pond GR, Roessner M, et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res. 2008;14:2763–2767
  17. Berry DL, Moinpour CM, Jiang CS, Pauler Ankerst D, Petrylak DP, Vinson LV, et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwestern oncology group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol. 2006;24:2828–2835
  18. Abratt RP, Brune D, Dimopoulos MA, et al. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol. 2004;15:1613–1621
  19. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17:2506–2513
  20. Ernst DS, Tannock IF, Winquist EW, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol. 2003;21:3335–3342
  21. Hudes G, Einhorn L, Ross E, et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier oncology group and fox chase network phase III trial. J Clin Oncol. 1999;17:3160–3166
  22. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol. 1996;14:1756–1764
  23. Dawson NA, Conaway M, Halabi S, et al. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma. Cancer. 2000;88:825–834
  24. Fossa SD, Aaronson N, Calais da Silva F, et al. Quality of life in patients with muscle-infiltrating bladder cancer and hormone-resistant prostatic cancer. Eur Urol. 1989;16:335–339
  25. Moinpour CM, Donaldson GW. Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: dynamically modified outcomes (DYNAMO) analysis of a randomized controlled trial. Qual Life Res. 2009;18:147–155
  26. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol. 2008;26:1148–1159
  27. Guyatt GH, Osoba D, Wu AW, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77:371–383
  28. Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the functional assessment of cancer therapy-prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health. 2009;12:124–129
  29. Hjermstad MJ, Fayers PM, Bjordal K, et al. Health-related quality of life in the general Norwegian population assessed by the European organization for research and treatment of cancer Coro quality-of-life questionnaire: the QLQ-C30. J Clin Oncol. 1998;16:1188–1196
  30. King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res. 1996;5:555–567
  31. Curran D, Fossa S, Aaronson N, et al. Baseline quality of life of patients with advanced prostate cancer. European organization for research and treatment of cancer (EORTC), genito-urinary tract cancer cooperative group (GUT-CCG). Eur J Cancer. 1997;33:1809–1814
  32. Sommers SD, Ramsey SD. A review of quality-of-life evaluations in prostate cancer. Pharmacoeconomics. 1999;16:127–130
  33. Fitzsimmons D, Gilbert J, Howse F, et al. A systematic review of the use and validation of health-related quality of life instruments in older cancer patients. Eur J Cancer. 2009;45:19–32
  34. Lichtman SM, Wildiers H, Chatelut E, et al. International society of geriatric oncology chemotherapy taskforce. Evaluation of chemotherapy in older patients – an analysis of the medical literature. J Clin Oncol. 2007;25:1832–1843
  35. Droz JP, Chaladaj A. Management of metastatic prostate cancer: the crucial role of geriatric assessment. BJU Int. 2008;101(Suppl. 2):23–29
  36. Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104:1998–2005
  37. Tannenbaum C, Ahmed S, Mayo N. What drives older women’s perceptions of health-related quality of life?. Qual Life Res. 2007;16:593–605
  38. Hickey A, Barker M, McGee H, et al. Measuring health-related quality of life in older patient populations: a review of current approaches. Pharmacoeconomics. 2005;23:971–993
  39. Butler J, Ciarrochi J. Psychological acceptance and quality of life in the elderly. Qual Life Res. 2007;16:607–615
  40. Kaasa S, Hjermstad MJ, Jordhoy MS, et al. Compliance in quality of life data: a Norwegian experience. Stat Med. 1998;17:623–632
  41. Blazeby JM, Avery K, Sprangers M, et al. Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol. 2006;24:3178–3186
  42. Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol. 1994;12:608–616
  43. Gotay CC, Kawamoto CT, Bottomley A, et al. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008;26:1355–1363
  44. Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol. 2008;26:2544–2549
  45. Armstrong AJ, Garrett-Mayer E, Yang YCO, Carducci MA, Tannock I, de Wit R, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007;25:3965–3970
  46. Kiecolt-Glaser JK, Robles TF, Heffner KL, et al. Psycho-oncology and cancer: psychoneuroimmunology and cancer. Ann Oncol. 2002;13(Suppl. 4):165–169
  47. Rummans TA, Clark MM, Sloan JA, et al. Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial. J Clin Oncol. 2006;24:635–642

PII: S0305-7372(10)00021-6

doi: 10.1016/j.ctrv.2010.02.001

Cancer Treatment Reviews
Volume 36, Issue 6 , Pages 501-506 , October 2010

Article Tools